Poolbeg Pharma (LSE:POLB) has now dosed eight of the roughly 30 participants planned for its POLB 001 TOPICAL trial, counting from the first dosing in July 2026 and following an earlier six-patient safety cohort. The trial is testing POLB 001 as a preventative treatment for cytokine release syndrome, and the company says more clinical sites have expressed interest in joining.
What was announced
On 28 September 2026 AIM-quoted Poolbeg Pharma plc (LSE:POLB) gave a recruitment update on TOPICAL, its clinical trial of POLB 001. The announcement said: "Following the previously announced six-patient safety cohort, a total of eight participants have now been dosed out of c.30, since the first patient dosed in July 2026."
On a calculation, eight of about 30 participants means around a quarter of planned enrolment has been dosed, leaving about 22 still to be recruited. The company said recruitment activity remains encouraging, with good engagement from investigators, participating centres and patients. It added that "further clinical sites have expressed interest in joining the trial, supporting ongoing recruitment and potential site expansion in the coming months."
The update covers enrolment only, and the company gave no new financial information. It includes no safety or efficacy data and gives no date for results.
The trial
TOPICAL is assessing POLB 001 as a potential preventative therapy for cytokine release syndrome (CRS). CRS is a potentially life-threatening side effect of some cancer immunotherapies. The trial enrols patients with relapsed or refractory multiple myeloma who are being treated with teclistamab, a bispecific antibody. The announcement does not name the trial's phase or describe how POLB 001 works, and it does not list the participating sites or countries.
In its 13 July 2026 announcement that the first patient had been dosed, Poolbeg said University College London Hospital had been activated as a site. It expected further sites to open shortly, and said Johnson & Johnson was supplying teclistamab to the company at no cost. The July announcement also said interim data were on track for late summer 2026. The 28 September update does not mention interim data or any change to that timetable.
Chief executive Jeremy Skillington said: "With eight participants dosed since mid-July and continued patient & investigator interest in the study, the trial continues to advance positively."
Background
Poolbeg describes itself as a clinical-stage biopharmaceutical company. It is aiming to make cancer immunotherapies safer by preventing CRS, which it says could allow treatments that are currently given in centralised specialist cancer centres to be delivered in community hospitals. Its July announcement noted that bispecific antibodies such as teclistamab are increasingly being used earlier in treatment. Poolbeg has referred to multi-billion-dollar peak sales potential for POLB 001 and to partnering discussions with several companies. These are the company's own statements, and no partnering terms have been announced.
Alongside POLB 001, Poolbeg is developing an oral encapsulated GLP-1 therapy for obesity, which it describes as "a patient-friendly therapy for obesity" offering a differentiated approach in one of the world's largest markets.
The company's chief financial officer is Ian O'Connell.
What to watch next
The next steps are further recruitment towards about 30 participants, any additional clinical sites joining the trial and any interim safety or efficacy readout. It is not yet clear from the company's disclosures when interim data will be published, or whether the late-summer 2026 timetable given in July still applies. Poolbeg has not given a date for completing enrolment, and any partnering developments would be announced separately.






Please wait processing your request...